Skip to main content
OpenTrials

Clinical trial condition

HER2-negative Breast Cancer

Explore clinical trials studying HER2-negative Breast Cancer. Study availability and eligibility vary by location and protocol.

109 public trials 55 recruiting studies
Refine in advanced search Browse all conditions

HER2-negative Breast Cancer trial results

Active, not recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979

Conditions
HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, PIK3CA Mutant Metastatic Breast Cancer
Locations
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
  • Penn State Cancer Institute Hershey, Pennsylvania, United States
  • University of Wisconsin Madison, Wisconsin, United States
View Trial Details
Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NCT03983954

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Adenoma, +79 more
Locations
  • Shalby Hospital Ahmedabad, Gujarat, India
  • National Cancer Institute Jhajjar, Haryana, India
  • All India Institute of Medical Sciences New Delhi, India
  • PMCH (Pacific Medical College & Hospital) Udaipur, Rajasthan, India
View Trial Details
Completed

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT06253195

Conditions
Advanced Solid Tumor, Breast Cancer, Breast Diseases, +14 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) Guangzhou, Guangdong, China
  • Guangxi Medical University Cancer Hospital Nanning, Guangxi, China
View Trial Details
Completed

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

NCT06570031

Conditions
Breast Diseases, Breast Neoplasms, Disease Attributes, +13 more
Locations
  • Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Chiba Cancer Center Chiba, Japan
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
View all 13 locations
View Trial Details

Related conditions